Loading clinical trials...

Pragmatic Trial of Messaging to Providers About Treatment of Chronic Kidney Disease | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Pragmatic Trial of Messaging to Providers About Treatment of Chronic Kidney Disease

NCT07430930•Yale University

Summary

This study is a cluster-randomized clinical trial to evaluate whether a tailored, user-centered, clinical decision support (CDS) tool can positively influence prescriber behavior and increase prescription of guideline-directed medical therapy (GDMT) among patients with Chronic Kidney Disease (CKD) across a single healthcare center.

Detailed Description

PROMPT-CKD is a single-system, cluster-randomized clinical trial to evaluate the effectiveness of a tailored, user-centered, clinical decision support (CDS) tool for the prescription of guideline-directed medical therapy (GDMT) in patients with Chronic Kidney Disease (CKD). Consented providers (physicians, DOs, PA, APRNs, and PharmDs within internal medicine, family medicine and nephrology departments) will be randomized to either an intervention group that will be exposed to the CDS tool, or to a control (usual care) group that will not be exposed to the CDS tool. Upon opening of the order entry screen in the patient's medical record, the CDS tool will automatically and immediately evaluate inclusion and exclusion criteria for the patient, and if all criteria are met, the patient will be automatically enrolled into the study under the randomization group of the provider who opened the chart. The CDS tool is a best practice alert that appears for each eligible patient with CKD at the level of the order entry screen in the patient's medical record. The alert informs the provider of the presence of CKD, details the patient's most current relevant lab values, and lists current GDMT prescribed. Additionally, the alert lists GDMT which is indicated for the patient but which is not currently prescribed. The alert will also contain an order set containing the indicated medications. Providers may choose to dismiss the alert and indicate the reason. Those in the control arm of the trial will not see alerts, however a "silent alert" will be generated that registers the patient into the study. These patients will receive care as usual. The primary outcome will assess the proportion of patients with one or more new eligible GDMT prescriptions within 90 days of randomization. Secondary outcomes include time to Major Adverse Kidney Events (MAKE), time to all-cause mortality, time to greater than 40% reduction in eGFR, time to end stage kidney disease (ESKD), time to all-cause hospitalization, and time to worsening of CKD stage.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male or female, aged ≥18 years
•2. Diagnosed with CKD defined by an eGFR ≤60 mL/min/1.732 on two occasions at least ≥3 months apart with most recent being ≤60 or eGFR 60-90 mL/min/1.73m2 with an uACR ≥30 mg/g or eGFR \>90 mL/min/1.73m2 with an uACR ≥30 mg/g.
•3. Eligible to receive at least 1 of the following CKD GDMT: ACEi/ARB, SGLT2i, MRA or GLP-1 RA based on the following criteria.
•4. To receive an ACEi/ARB: eGFR ≥15 ml/min/1.732 and have diagnosis of hypertension based on ICD10 code or proteinuria (uACR ≥30 mg/g).
•5. To receive an SGLT2i: have heart failure (defined by ICD10 code); or T2D; or uACR ≥200 mg/g; or eGFR ≥20 ml/min/1.732.
•6. To receive an MRA: ns-MRA: have an eGFR ≥25 ml/min/1.732, diagnosis of T2D, normal serum potassium (≤4.8 mmol/L) and albuminuria (\>30 mg/g). s-MRA: have an eGFR ≥45 ml/min/1.732 and heart failure, hyperaldosteronism, or refractory hypertension.
•7. To receive a GLP-1 RA: have T2D.
•8. Ability to take oral medication.

Exclusion Criteria

•1. Allergy to the GDMT for which the patient is eligible
•2. End-stage kidney disease
•3. CKD stage 5 (eGFR \<15 ml/min/1.73m2)
•4. Glomerulonephritis (by ICD-10 code)
•5. Polycystic kidney disease (by ICD-10 code)
•6. History of kidney transplant
•7. End-stage heart failure
•8. Eligible to receive ACEi/ARB but having blood pressure \<110/70 mmHg or have known renal artery stenosis
•9. Eligible to receive SGLT2i but pregnant or breastfeeding, type 1 DM, history of euglycemic diabetic ketoacidosis or Fournier's gangrene based on ICD10 code.
•10. Eligible to receive MRA but serum potassium ≥5 mmol/L, have office SBP \<100 mmHg, adrenal insufficiency based on ICD10 code or concomitant treatment with CYP3A4 inhibitors (Strong: grapefruit, grapefruit juice, itraconazole. Moderate: erythromycin. Weak: amiodarone).
+2 more criteria

Locations (1)

Yale New Haven Health

New Haven, Connecticut, United States

Key Dates

Start Date

March 1, 2026

Primary Completion Date

June 1, 2027

Completion Date

March 1, 2028

Last Updated

February 24, 2026

Enrollment

1,000

ESTIMATED participants

Conditions

Chronic Kidney Diseases

Interventions

Best practice alert and order set for CKD

OTHER

Contacts

Francis P Wilson, MD MSCE

CONTACT

203-737-1704 francis.p.wilson@yale.edu

Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis

NCT04592640

Chronic Kidney DiseasesCalciphylaxis+4 more

View study

RECRUITINGNA

Handgrip Exercise Training and CKD

NCT07094906

Chronic Kidney Diseases

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 24, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pragmatic Trial of Messaging to Providers About Treatment of Chronic Kidney Disease

Inclusion Criteria

Exclusion Criteria

Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis

Handgrip Exercise Training and CKD

Eye-Brain-Kidney in CKD

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect